Dalbavancin for the treatment of acute bacterial skin and skin structure infections

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 13, 2015, Pages 2073-2081

  Ramdeen, Sheena ^a   Boucher, Helen W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute bacterial skin and skin structure infections; dalbavancin; gram positive bacteria; lipoglycopeptide

Indexed keywords

DALBAVANCIN; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ACUTE DISEASE; ANAPHYLAXIS; AREA UNDER THE CURVE; ARM PAIN; ARTICLE; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; CELLULITIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; LEUKOPENIA; NAUSEA; NONHUMAN; OTOTOXICITY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THRUSH; TISSUE DISTRIBUTION; URINARY EXCRETION; URTICARIA; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBIOTIC RESISTANCE; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF LIFE TIME; SKIN DISEASES, BACTERIAL;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; SKIN DISEASES, BACTERIAL; TEICOPLANIN;

EID: 84939778503     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1075508     Document Type: Article

References (61)

1. Food and Drug Administration. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf
2. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15 (9): 1516-18
3. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-Tissue infections. Arch Intern Med 2008; 168 (14): 1585-91
4. May L, Mullins P, Pines J. Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006-2010. Acad Emerg Med 2014; 21 (1): 17-24
5. Wilder JR, Wegener DT, David MZ, et al a national survey of skin infections, care behaviors and MRSA knowledge in the United States. PLoS ONE 2014; 9 (8): e104277
6. Dukic VM, Lauderdale DS, Wilder J, et al. Epidemics of community-Associated methicillin-resistant Staphylococcus aureus in the United States: A meta-Analysis. PLoS ONE 2013; 8 (1): e52722
7. Suaya JA, Mera RA, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis 2014; 14: 296-303
8. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-Tissue infections in a us population: A retrospective population-based study. BMC Infect Dis 2013; 13: 252
9. Johnson AP. Methicillin-resistant Staphylococcus aureus: The European landscape. J Antimicrob Chemother 2011; 66 (Suppl 4): iv43-8
10. Dryden M, Andrasevic AT, Bassetti M, et al a European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010; 16 (Suppl 1): 3-30
11. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59 (2): e10-52
12. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010; 10 (5): 516-21
13. Long SW, Olsen RJ, Mehta SC, et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2014; 58 (11): 6668-74
14. Jenkins TC, Sabel AL, Sarcone EE, et al. Skin and soft-Tissue infections requiring hospitalization at an academic medical center: Opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51 (8): 895-903
15. Food and Drug Administration. FDA approves dalvance to treat skin infections [Internet]. 2014. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm398724.htm. [Last accessed 21 March 2015]
16. European Medicines Agency. Xydalba authorisation details [Internet]. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human-med-001848.jsp&mid=WC0b01ac058001d124. [Last accessed 17 April 2015]
17. Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370 (23): 2180-90
18. Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014; 14 (8): 696-705
19. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-An antibiotic enters obsolescence. Clin Infect Dis 2007; 44 (12): 1543-8
20. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: Where are we? Ann Clin Microbiol Antimicrob 2013; 12: 22
21. Pew Charitable Trusts. Antibiotics currently in clinical development [Internet]. 2014. Available from: http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development. [Last accessed 6 April 2015]
22. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005; 55 (Suppl 2): ii15-20
23. Economou NJ, Nahoum V, Weeks SD, et al a carrier protein strategy yields the structure of dalbavancin. J Am Chem Soc 2012; 134 (10): 4637-45
24. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006; 58 (4): 802-5
25. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49 (2): 770-2
26. Dowell JA, Goldstein BP, Buckwalter M, et al. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 2008; 48 (9): 1063-8
27. Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48 (4): 1118-23
28. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51 (5): 1633-42
29. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48 (2): 137-43
30. Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53 (4): 307-10
31. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005; 11 (2): 95-100
32. Biedenbach DJ, Ross JE, Fritsche TR, et al. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol 2007; 45 (3): 998-1004
33. Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against Staphylococci and Streptococci in 5 European countries: Results from the DECIDE surveillance program (2007). Diagn Microbiol Infect Dis 2009; 64 (2): 177-84
34. Goldstein EJ, Citron DM, Warren YA, et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006; 50 (8): 2875-9
35. Huang V, Cheung CM, Kaatz GW, Rybak MJ. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-Associated and multidrug-resistant hospital-Associated meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2010; 35 (1): 25-9
36. Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005; 55 (Suppl 2): ii21-4
37. Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007; 51 (4): 1150-4
38. Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States surveillance program (2004). Diagn Microbiol Infect Dis 2006; 54 (2): 149-53
39. Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009; 53 (3): 1260-3
40. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: Report from the SENTRY antimicrobial surveillance program (2011). Diagn Microbiol Infect Dis 2013; 75 (3): 304-7
41. Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 2013; 76 (1): 122-3
42. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and Corynebacteria. Antimicrob Agents Chemother 2003; 47 (6): 1968-71
43. Jones RN, Stilwell MG. Comprehensive update of dalbavancin activity when tested against uncommonly isolated Streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagn Microbiol Infect Dis 2013; 76 (2): 239-40
44. Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents 2006; 27 (6): 557-60
45. Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005; 55 (Suppl 2): ii31-5
46. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48 (3): 940-5
47. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005; 55 (Suppl 2): ii25-30
48. Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007; 60 (3): 681-4
49. Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 2015; 59 (4): 1849-55
50. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005; 45 (11): 1279-87
51. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009; 49 (4): 465-76
52. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-Tissue infections. Clin Infect Dis 2003; 37 (10): 1298-303
53. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41 (10): 1407-15
54. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370 (23): 2169-79
55. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005; 40 (3): 374-80
56. Campbell K, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide. J Am Acad Audiol 2003; 14 (3): 157-68
57. Dunne MW, Zhou M, Darpo B a thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 2015; 45 (4): 393-8
58. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006; 58 (3): 627-31
59. Durata Therapeutics International B.V. Dalbavancin for injection for treatment of acute bacterial skin and skin structure infections. Briefing Document. FDA Anti-Infective Drugs Advisory Committee: 2014. Report No: ND 021-883
60. United States Food and Drug Administration Center for Drug Evaluation and Research. Novel new drugs 2014 summary. 2015
61. National Institutes of Health. Search results for dalbavancin [Internet]. 2015. Available from: https://clinicaltrials.gov/ct2/results?intr=%22Dalbavancin%22. [Last accessed 17 April 2015]